Citations (122)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Stéphane Yanda Tongo, Benjamin Longo-Mbenza, Antoine Molua Aundu, Raoul Gombet, Jean Robert Makulo Risasi, Christian Kisoka Lusunsi, Héritier Mawalala Malengele & Augustin Nge Okwe. (2022) Are Any Changes in Carotid Intima–Media Thickness Associated with Cardiometabolic Risk Among Adult Bantu Central African Hypertensive Patients from Monkole and Biamba Marie Mutombo Hospitals?. Vascular Health and Risk Management 18, pages 453-461.
Read now
Read now
Srinivas R. Nalamachu & Binit Shah. (2022) Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion. Postgraduate Medicine 134:4, pages 388-394.
Read now
Read now
Mohammad Algarni, Muhammad Abdul Hadi, Asma Yahyouche, Sajid Mahmood & Zahraa Jalal. (2021) A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults. Journal of Pharmaceutical Policy and Practice 14:1.
Read now
Read now
James T. Harnett, Alison M. Dines, David M. Wood, John R. H. Archer & Paul I. Dargan. (2020) Cold water extraction of codeine/paracetamol combination products: a case series and literature review. Clinical Toxicology 58:2, pages 107-111.
Read now
Read now
Eric R. Kinzler, Carmela Pantaleon, Matthew S. Iverson & Stefan Aigner. (2019) Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation. The American Journal of Drug and Alcohol Abuse 45:4, pages 377-384.
Read now
Read now
Sebastiano Mercadante. (2019) Potential strategies to combat the opioid crisis. Expert Opinion on Drug Safety 18:3, pages 211-217.
Read now
Read now
Jeffrey Vietri, Elizabeth T Masters, Alexandra I Barsdorf & Jack Mardekian. (2018) Cost of opioid medication abuse with and without tampering in the USA. ClinicoEconomics and Outcomes Research 10, pages 433-442.
Read now
Read now
Andrea Fanelli, Maria Cristina Sorella & Daniela Ghisi. (2018) Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain. Expert Review of Clinical Pharmacology 11:12, pages 1157-1162.
Read now
Read now
Joseph V. Pergolizzi$suffix/text()$suffix/text(), Robert Taylor$suffix/text()$suffix/text(), Jo Ann LeQuang & Robert B. Raffa. (2018) What’s holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders. Expert Opinion on Drug Delivery 15:6, pages 567-576.
Read now
Read now
Lynn R. Webster, Eugene R. Viscusi, Colville Brown & Jeffrey M. Dayno. (2018) Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. Current Medical Research and Opinion 34:5, pages 893-901.
Read now
Read now
Edward J. Cone, August R. Buchhalter, Karsten Lindhardt, Torben Elhauge & Jeffrey M. Dayno. (2017) The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets. The American Journal of Drug and Alcohol Abuse 43:3, pages 291-298.
Read now
Read now
Carl L. Roland, Beatrice Setnik & David A. Brown. (2017) Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure. Postgraduate Medicine 129:1, pages 12-21.
Read now
Read now
Lynn R. Webster, John Markman, Edward J. Cone & Gwendolyn Niebler. (2017) Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine 129:1, pages 102-110.
Read now
Read now
Miroslav Backonja, Lynn R. Webster, Beatrice Setnik, Almasa Bass, Kenneth W. Sommerville, Kyle Matschke, Bimal K. Malhotra & Gernot Wolfram. (2016) Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. The American Journal of Drug and Alcohol Abuse 42:5, pages 539-549.
Read now
Read now
Stephanie Lake & Mary Clare Kennedy. (2016) Health outcomes associated with illicit prescription opioid injection:A systematic review. Journal of Addictive Diseases 35:2, pages 73-91.
Read now
Read now
Maciej Gasior, Mary Bond & Richard Malamut. (2016) Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine 128:1, pages 85-96.
Read now
Read now
Wayne Wakeland, Alexandra Nielsen & Peter Geissert. (2015) Dynamic model of nonmedical opioid use trajectories and potential policy interventions. The American Journal of Drug and Alcohol Abuse 41:6, pages 508-518.
Read now
Read now
David J Mastropietro & Hossein Omidian. (2015) Abuse-deterrent formulations: part 1 – development of a formulation-based classification system. Expert Opinion on Drug Metabolism & Toxicology 11:2, pages 193-204.
Read now
Read now
Robert B Raffa, Robert Taylor$suffix/text()$suffix/text() & Joseph V Pergolizzi$suffix/text()$suffix/text(). (2014) Sequestered naltrexone in sustained release morphine or oxycodone – a way to inhibit illicit use?. Expert Opinion on Drug Safety 13:2, pages 181-190.
Read now
Read now
Michael J Brennan. (2013) Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare 6, pages 265-280.
Read now
Read now
R.
Terry Furst. (2013) Suboxone Misuse Along the Opiate Maintenance Treatment Pathway. Journal of Addictive Diseases 32:1, pages 53-67.
Read now
Read now
Articles from other publishers (101)
Chao Cai, Sophia Knudsen & Kyle Weant. (2023) OPIOID PRESCRIBING BY EMERGENCY PHYSICIANS: TRENDS STUDY OF MEDICARE PART D PRESCRIBER DATA 2013–2019. The Journal of Emergency Medicine.
Crossref
Crossref
Marc López‐Cano, Joan Font, Ester Aso, Kristoffer Sahlholm, Gisela Cabré, Jesús Giraldo, Yves De Koninck, Jordi Hernando, Amadeu Llebaria, Víctor Fernández‐Dueñas & Francisco Ciruela. (2021) Remote local photoactivation of morphine produces analgesia without opioid‐related adverse effects. British Journal of Pharmacology 180:7, pages 958-974.
Crossref
Crossref
Jennifer Jewell, Joshua Black, Matthew Ellis, Heather Olsen, Janetta Iwanicki & Richard Dart. (2023) A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population. Clinical Drug Investigation 43:3, pages 197-203.
Crossref
Crossref
Suzanne K. Vosburg, Stephen V. Faraone, Elizabeth Riley, Timothy Whitaker, Jessica Kardish, David Baker, Scott H. Kollins & Craig R. Rush. (2022) Intranasal Use of Prescription Stimulants Among Adults Aged 18 to 30: Results From A Crowdsourcing Platform. Journal of Attention Disorders 27:1, pages 14-25.
Crossref
Crossref
Lynn R. Webster, Jacqueline Cater & Thomas Smith. (2022) Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial. Pain and Therapy 11:3, pages 817-825.
Crossref
Crossref
Leyla Rezaei, Saikishore Meruva & Maureen D. Donovan. (2021) Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets. AAPS PharmSciTech 23:1.
Crossref
Crossref
Daniel C. Beachler, Kelsey Hall, Renu Garg, Geetanjoli Banerjee, Ling Li, Luke Boulanger, Huseyin Yuce & Alexander M. Walker. (2022) An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose. The Clinical Journal of Pain 38:6, pages 396-404.
Crossref
Crossref
Suzanne K. Vosburg, Rebekkah S. Robbins, Kevin M. Antshel, Stephen V. Faraone & Jody L. Green. (2021) Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit. Addictive Behaviors Reports 14, pages 100376.
Crossref
Crossref
Svetlana Beilfuss & Sebastian Linde. (2021) Pharmaceutical opioid marketing and physician prescribing behavior. Health Economics 30:12, pages 3159-3185.
Crossref
Crossref
Suzanne K. Vosburg, Stephen V. Faraone, Jeffrey H. Newcorn, Anthony L. Rostain, Robert L. Findling, Stephen F. Butler, Taryn Dailey Govoni & Jody L. Green. (2020) Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHAT™). Journal of Attention Disorders 25:13, pages 1859-1870.
Crossref
Crossref
Margarida L. F. Martins, Erica A. Wilthagen, Eugenia Oviedo-Joekes, Jos H. Beijnen, Nelda de Grave, Ambros Uchtenhagen, Thilo Beck, Wim Van den Brink & Alfred H. Schinkel. (2021) The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug and Alcohol Dependence 227, pages 108984.
Crossref
Crossref
Saeid Raofi, Minori Kinjo, Dajun Sun, Zhichuan Li, Heather Boyce, Karthika Natarajan, Mitchell Frost, Liang Zhao, Markham Luke, Robert Lionberger, Debra Kelsh & Myong‐Jin Kim. (2021) Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users. Clinical and Translational Science 14:5, pages 1977-1987.
Crossref
Crossref
Mohammad O. Tuhin, Krystal Cheng, Muhammad Naveed, Bahar Aliakbarian & Muhammad Rabnawaz. (2021) A Dual-Wall 3D-Printed Anti-tampering Medical Bottle. Journal of Packaging Technology and Research 5:2, pages 89-95.
Crossref
Crossref
Thomas Wojciechowski. (2020) Antisocial Personality Disorder as a Risk Factor for Opioid Use: The Dual Mediating Roles of Antisocial Attitudes and Self-Control. Journal of Drug Issues 51:2, pages 268-283.
Crossref
Crossref
Shannon GaddNicholas CoxJames Samuelson, Amy KenneyKyle TurnerGerald Cochran. (2021) Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. Therapeutic Drug Monitoring 43:1, pages 35-41.
Crossref
Crossref
Suzanne K. Vosburg, Rebekkah S. Robbins, Kevin M. Antshel, Stephen V. Faraone & Jody L. Green. (2021) Characterizing Pathways of Non-oral Prescription Stimulant Non-medical Use Among Adults Recruited From Reddit. Frontiers in Psychiatry 11.
Crossref
Crossref
Duilio Balsamo, Paolo Bajardi, Alberto Salomone & Rossano Schifanella. (2021) Patterns of Routes of Administration and Drug Tampering for Nonmedical Opioid Consumption: Data Mining and Content Analysis of Reddit Discussions. Journal of Medical Internet Research 23:1, pages e21212.
Crossref
Crossref
Meera Shah, Ryan Wong, Laura Ball, Klajdi Puka, Charlie Tan, Esfandiar Shojaei, Sharon Koivu & Michael Silverman. (2020) Risk factors of infective endocarditis in persons who inject drugs. Harm Reduction Journal 17:1.
Crossref
Crossref
Xin Feng, Ahmed Zidan, Nahid S. Kamal, Xiaoming Xu, Dajun Sun, Ross Walenga, Heather Boyce, Celia N. Cruz & Muhammad Ashraf. (2020) Assessing Drug Release from Manipulated Abuse Deterrent
Formulations. AAPS PharmSciTech 21:2.
Crossref
Crossref
Angéline Adam, Robert P. Schwartz, Li-Tzy Wu, Geetha Subramaniam, Eugene Laska, Gaurav Sharma, Saima Mili & Jennifer McNeely. (2019) Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening tool. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Eric R. Kinzler, Carmela Pantaleon, Matthew Iverson & Stefan Aigner. (2019) A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. Advances in Therapy 36:9, pages 2394-2401.
Crossref
Crossref
Lynn R. Webster, Eric R. Kinzler, Carmela Pantaleon, Matthew Iverson & Stefan Aigner. (2019) Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Advances in Therapy 36:7, pages 1730-1740.
Crossref
Crossref
Saikishore Meruva & Maureen D. Donovan. (2019) Effects of Drug-Polymer Interactions on Tablet Properties During
the Development of Abuse-Deterrent Dosage Forms. AAPS PharmSciTech 20:3.
Crossref
Crossref
Lewis S. Nelson. (2019) Are abuse-deterrent opioid formulations all they are crushed up to be?. Addiction 114:3, pages 401-402.
Crossref
Crossref
Pavan Kumar Nukala, Siddhant Palekar, Manali Patki & Ketan Patel. (2019) Abuse Deterrent Immediate Release Egg-Shaped Tablet (Egglets)
Using 3D Printing Technology: Quality by Design to Optimize Drug Release and
Extraction. AAPS PharmSciTech 20:2.
Crossref
Crossref
Almasa Bass, Lynn R. Webster, Kyle T. Matschke, Bimal K. Malhotra & Gernot Wolfram. (2019) Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study. Therapeutic Advances in Drug Safety 10, pages 204209861882127.
Crossref
Crossref
Matthew S. Ellis, Theodore J. Cicero, Richard C. Dart & Jody L. Green. (2019) Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. Pharmacoepidemiology and Drug Safety 28:1, pages 117-121.
Crossref
Crossref
Natasa Gisev, Sallie-Anne Pearson, Timothy Dobbins, David C Currow, Fiona Blyth, Sarah Larney, Adrian Dunlop, Richard P Mattick, Andrew Wilson & Louisa Degenhardt. (2018) Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. BMJ Open 8:12, pages e025840.
Crossref
Crossref
Theodore J. Cicero & Matthew S. Ellis. (2018) Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality. Addictive Behaviors 86, pages 11-16.
Crossref
Crossref
Stephen F Butler, Ryan A Black & Alison B Fleming. (2018) Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration. Pain Medicine 19:8, pages 1613-1627.
Crossref
Crossref
Eric R. Kinzler, Carmela Pantaleon & Stefan Aigner. (2018) Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. Clinical Therapeutics 40:8, pages 1357-1365.
Crossref
Crossref
David L. Murphy, Jacob A. Lebin, Stevan G. Severtson, Heather A. Olsen, Nabarun Dasgupta & Richard C. Dart. (2018) Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. Drug Safety 41:8, pages 787-795.
Crossref
Crossref
Jared Beaumont, Theresa A. Cassidy, Natasha Oyedele, Sven Guenther & Travis C. Mickle. (2018) Characterizing Abuse Progression of Immediate-Release Hydrocodone Combination Products. Journal of Drug Issues 48:3, pages 312-326.
Crossref
Crossref
Stephen F. Butler, Emily C. McNaughton, Ryan A. Black & Theresa A. Cassidy. (2018) Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product. The Clinical Journal of Pain 34:7, pages 618-628.
Crossref
Crossref
Briony Larance, Timothy Dobbins, Amy Peacock, Robert Ali, Raimondo Bruno, Nicholas Lintzeris, Michael Farrell & Louisa Degenhardt. (2018) The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. The Lancet Psychiatry 5:2, pages 155-166.
Crossref
Crossref
Lynn R. Webster, Carmela Pantaleon, Matthew Iverson, Michael D. Smith, Eric R. Kinzler & Stefan Aigner. (2018) Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management 2018, pages 1-10.
Crossref
Crossref
Stephen F. Butler, Ryan A. Black, Stevan Geoffrey Severtson, Richard C. Dart & Jody L. Green. (2018) Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. Journal of Substance Abuse Treatment 84, pages 42-49.
Crossref
Crossref
Michael J Brennan, Ernest A Kopecky, Ann Marseilles, Melinda O'Connor & Alison B Fleming. (2017)
The comparative pharmacokinetics of physical manipulation by crushing of Xtampza
®
ER compared with OxyContin
®
. Pain Management 7:6, pages 461-472.
Crossref
Crossref
Urszula Skupio, Magdalena Sikora, Michal Korostynski, Agnieszka Wawrzczak-Bargiela, Marcin Piechota, Joanna Ficek & Ryszard Przewlocki. (2017) Behavioral and transcriptional patterns of protracted opioid self-administration in mice. Addiction Biology 22:6, pages 1802-1816.
Crossref
Crossref
Theresa A. Cassidy, Natasha Oyedele, Travis C. Mickle, Sven Guenther & Simon H. Budman. (2017) Patterns of abuse and routes of administration for immediate-release hydrocodone combination products. Pharmacoepidemiology and Drug Safety 26:9, pages 1071-1082.
Crossref
Crossref
Christopher M. Jones, Aleta Christensen & R. Matthew Gladden. (2017) Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug and Alcohol Dependence 176, pages 89-95.
Crossref
Crossref
Jody L. Green, Becki Bucher Bartelson, M. Claire Le Lait, Carl L. Roland, Elizabeth T. Masters, Jack Mardekian, J. Elise Bailey & Richard C. Dart. (2017) Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and Alcohol Dependence 175, pages 140-145.
Crossref
Crossref
Christopher M. Jones, Pradip K. Muhuri & Peter G. Lurie. (2017) Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. The Clinical Journal of Pain 33:5, pages 452-461.
Crossref
Crossref
Neil C Lax, Renxun Chen, Sarah R Leep, Kathryn E Uhrich, Lei Yu & Benedict J Kolber. (2017) PolyMorphine provides extended analgesic-like effects in mice with spared nerve injury. Molecular Pain 13, pages 174480691774347.
Crossref
Crossref
Evelyn Hearne, Jean-Paul Cornelius Grund, Marie Claire Van Hout & Jim McVeigh. (2016) A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy. Harm Reduction Journal 13:1.
Crossref
Crossref
Scott P. Novak, Anders Håkansson, Jose Martinez-Raga, Jens Reimer, Karol Krotki & Sajan Varughese. (2016) Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 16:1.
Crossref
Crossref
Adam C. Fisher, Sau L. Lee, Daniel P. Harris, Lucinda Buhse, Steven Kozlowski, Lawrence Yu, Michael Kopcha & Janet Woodcock. (2016) Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. International Journal of Pharmaceutics 515:1-2, pages 390-402.
Crossref
Crossref
Yvette N. Lamb, Karly P. Garnock-Jones & Susan J. Keam. (2016) Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain. Drugs 76:18, pages 1759-1769.
Crossref
Crossref
Jeff Gudin. (2016) Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain. Pain and Therapy 5:2, pages 171-186.
Crossref
Crossref
Charlotte Martin, Andy De Baerdemaeker, Jan Poelaert, Annemieke Madder, Richard Hoogenboom & Steven Ballet. (2016) Controlled-release of opioids for improved pain management. Materials Today 19:9, pages 491-502.
Crossref
Crossref
Stevan Geoffrey Severtson, Matthew S. Ellis, Steven P. Kurtz, Andrew Rosenblum, Theodore J. Cicero, Mark W. Parrino, Michael K. Gilbert, Mance E. Buttram, Nabarun Dasgupta, Becki BucherBartelson, Jody L. Green & Richard C. Dart. (2016) Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence 168, pages 219-229.
Crossref
Crossref
Martin E Hale, Derek Moe, Mary Bond, Maciej Gasior & Richard Malamut. (2016) Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Management 6:5, pages 497-508.
Crossref
Crossref
Lynn R. Webster, Michael D. Smith, John Lawler, Karsten Lindhardt & Jeffrey M. Dayno. (2016) Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. Pain Medicine, pages pnw219.
Crossref
Crossref
Stephen C. Harris, Alessandra Cipriano, Ram P. Kapil, Naama Levy-Cooperman, Salvatore V. Colucci, Pierre Geoffroy & Talar Hopyan. (2016) Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. Pain Medicine, pages pnw208.
Crossref
Crossref
Michael D. Smith, Lynn R. Webster, John Lawler, Karsten Lindhardt & Jeffrey M. Dayno. (2016) Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. Pain Medicine, pages pnw174.
Crossref
Crossref
Amy Peacock, Raimondo Bruno, Briony Larance, Nick Lintzeris, Suzanne Nielsen, Robert Ali, Timothy Dobbins & Louisa Degenhardt. (2016) Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. Drug and Alcohol Dependence 166, pages 125-133.
Crossref
Crossref
PM Coplan, HD Chilcoat, SF Butler, EM Sellers, A Kadakia, V Harikrishnan, JD Haddox & RC Dart. (2016) The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics 100:3, pages 275-286.
Crossref
Crossref
Julien Maincent & Feng Zhang. (2016) Recent advances in abuse-deterrent technologies for the delivery of opioids. International Journal of Pharmaceutics 510:1, pages 57-72.
Crossref
Crossref
Shannon Ruzycki, Mark Yarema, Michael Dunham, Hossein Sadrzadeh & Alain Tremblay. (2015) Intranasal Fentanyl Intoxication Leading to Diffuse Alveolar Hemorrhage. Journal of Medical Toxicology 12:2, pages 185-188.
Crossref
Crossref
Catherine S. Hwang, Lydia W. Turner, Stefan P. Kruszewski, Andrew Kolodny & G. Caleb Alexander. (2016) Primary Care Physicians’ Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. The Clinical Journal of Pain 32:4, pages 279-284.
Crossref
Crossref
Xiaoming Xu, Abhay Gupta, Manar Al-Ghabeish, Silvia N. Calderon & Mansoor A. Khan. (2016) Risk based in vitro performance assessment of extended release abuse deterrent formulations. International Journal of Pharmaceutics 500:1-2, pages 255-267.
Crossref
Crossref
Stephen C. Harris, Alessandra Cipriano, Salvatore V. Colucci, Ram P. Kapil, Pierre Geoffroy, Talar Hopyan & Naama Levy-Cooperman. (2015) Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. Pain Medicine, pages pnv004.
Crossref
Crossref
Nathaniel Katz, Ernest A. Kopecky, Melinda O'Connor, Robert H. Brown & Alison B. Fleming. (2015) A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain 156:12, pages 2458-2467.
Crossref
Crossref
Amy Peacock, Louisa Degenhardt, Antonia Hordern, Briony Larance, Elena Cama, Nancy White, Ivana Kihas & Raimondo Bruno. (2015) Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. International Journal of Drug Policy 26:12, pages 1265-1272.
Crossref
Crossref
Beatrice Setnik, Candace Bramson, Almasa Bass, Naama Levy-Cooperman, Bimal Malhotra, Kyle Matschke, Kenneth W. Sommerville, Gernot Wolfram & Pierre Geoffroy. (2015) Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users. The Journal of Clinical Pharmacology 55:12, pages 1351-1361.
Crossref
Crossref
Briony Larance, Nicholas Lintzeris, Raimondo Bruno, Amy Peacock, Elena Cama, Robert Ali, Ivana Kihas, Antonia Hordern, Nancy White & Louisa Degenhardt. (2015) The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment 58, pages 51-61.
Crossref
Crossref
Edward J. Cone, Anne Z. DePriest, Rebecca Heltsley, David L. Black, John M. Mitchell, Charles LoDico & Ron Flegel. (2015) Prescription Opioids. IV: Disposition of Hydrocodone in Oral Fluid and Blood Following Single-Dose Administration. Journal of Analytical Toxicology 39:7, pages 510-518.
Crossref
Crossref
Kuan Gandelman, Michael Lamson, Candace Bramson, Kyle Matschke, Joanne Salageanu & Bimal Malhotra. (2015) Single- and multiple-dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended-release oxycodone with sequestered naltrexone 40 mg twice daily to oxycontin 40 mg twice daily and extended-release oxyco. Clinical Pharmacology in Drug Development 4:5, pages 361-369.
Crossref
Crossref
Kuan Gandelman, Michael Lamson, Joanne Salageanu, Candace Bramson, Kyle Matschke & Bimal Malhotra. (2015) Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. Clinical Pharmacology in Drug Development 4:5, pages 370-376.
Crossref
Crossref
Louisa Degenhardt, Raimondo Bruno, Robert Ali, Nicholas Lintzeris, Michael Farrell & Briony Larance. (2015) The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence 151, pages 56-67.
Crossref
Crossref
Xiaofan Li, Daryl Shorter & Thomas Kosten. (2015) Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic. Current Treatment Options in Psychiatry 2:2, pages 122-135.
Crossref
Crossref
E. J. Cone, A. Z. DePriest, R. Heltsley, D. L. Black, J. M. Mitchell, C. LoDico & R. Flegel. (2015) Prescription Opioids. III. Disposition of Oxycodone in Oral Fluid and Blood Following Controlled Single-Dose Administration. Journal of Analytical Toxicology 39:3, pages 192-202.
Crossref
Crossref
Andrew Kolodny, David T. CourtwrightCatherine S. HwangPeter KreinerJohn L. EadieThomas W. ClarkG. Caleb Alexander. (2015) The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. Annual Review of Public Health 36:1, pages 559-574.
Crossref
Crossref
Louisa Degenhardt, Briony Larance, Raimondo Bruno, Nicholas Lintzeris, Robert Ali & Michael Farrell. (2015) Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction 110:2, pages 226-237.
Crossref
Crossref
Catherine S. Hwang, Hsien-Yen Chang & G. Caleb Alexander. (2015) Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiology and Drug Safety 24:2, pages 197-204.
Crossref
Crossref
Harry J. GouldIIIIII & Dennis Paul. (2015) Hydrocodone extended-release: Pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy. Pharmacological Research 91, pages 99-103.
Crossref
Crossref
Catherine L O’Grady, Hilary L Surratt, Steven P Kurtz & Maria A Levi-Minzi. (2014) Nonmedical prescription drug users in private vs. public substance abuse treatment: a cross sectional comparison of demographic and HIV risk behavior profiles. Substance Abuse Treatment, Prevention, and Policy 9:1.
Crossref
Crossref
Jeffrey Vietri, Ashish V. Joshi, Alexandra I. Barsdorf & Jack Mardekian. (2014) Prescription Opioid Abuse and Tampering in the United States: Results of a Self-Report Survey. Pain Medicine 15:12, pages 2064-2074.
Crossref
Crossref
Edward M. Sellers, Megan J. Shram & Kerri A. Schoedel. (2014) The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Pharmaceutical Medicine 28:6, pages 317-327.
Crossref
Crossref
Nelson E. Sessler, Jerod M. Downing, Hrishikesh Kale, Howard D. Chilcoat, Todd F. Baumgartner & Paul M. Coplan. (2014) Reductions in reported deaths following the introduction of extended‐release oxycodone (OxyContin) with an abuse‐deterrent formulation. Pharmacoepidemiology and Drug Safety 23:12, pages 1238-1246.
Crossref
Crossref
Jon E. ZibbellRachel Hart-MalloyJohn BarryLillian FanColleen Flanigan. (2014) Risk Factors for HCV Infection Among Young Adults in Rural New York Who Inject Prescription Opioid Analgesics. American Journal of Public Health 104:11, pages 2226-2232.
Crossref
Crossref
Marie Claire Van Hout. (2014) Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Drug Testing and Analysis 6:7-8, pages 778-787.
Crossref
Crossref
Jennifer R. Havens, Carl G. Leukefeld, Angela M. DeVeaugh-Geiss, Paul Coplan & Howard D. Chilcoat. (2014) The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug and Alcohol Dependence 139, pages 9-17.
Crossref
Crossref
Louis Alexander, Richard O. Mannion, Brianne Weingarten, Richard J. Fanelli & Gary L. Stiles. (2014) Development and impact of prescription opioid abuse deterrent formulation technologies. Drug and Alcohol Dependence 138, pages 1-6.
Crossref
Crossref
Bing Cai, Håkan Engqvist & Susanne Bredenberg. (2014) Evaluation of the resistance of a geopolymer-based drug delivery system to tampering. International Journal of Pharmaceutics 465:1-2, pages 169-174.
Crossref
Crossref
Stephen C. Harris, Peter J. Perrino, Ira Smith, Megan J. Shram, Salvatore V. Colucci, Cynthia Bartlett & Edward M. Sellers. (2013) Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse‐deterrent controlled‐release tablets in recreational opioid users. The Journal of Clinical Pharmacology 54:4, pages 468-477.
Crossref
Crossref
Theresa A. Cassidy, Pronabesh DasMahapatra, Ryan A. Black, Matthew S. Wieman & Stephen F. Butler. (2014) Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation. Pain Medicine 15:3, pages 440-451.
Crossref
Crossref
Alexandra Nielsen & Wayne Wakeland. 2014. Simulation and Modeling Methodologies, Technologies and Applications. Simulation and Modeling Methodologies, Technologies and Applications
169
181
.
Paul M. Coplan, Hrishikesh Kale, Lauren Sandstrom, Craig Landau & Howard D. Chilcoat. (2013) Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended‐release oxycodone with abuse‐deterrent characteristics. Pharmacoepidemiology and Drug Safety 22:12, pages 1274-1282.
Crossref
Crossref
M. Okic, L. Cnossen, J. A. Crifasi, C. Long & E. K. Mitchell. (2013) Opioid Overdose Mortality in Kansas, 2001-2011: Toxicologic Evaluation of Intent. Journal of Analytical Toxicology 37:9, pages 629-635.
Crossref
Crossref
Edward M Sellers, Peter J Perrino, Salvatore V Colucci & Stephen C Harris. (2013)
Attractiveness of reformulated OxyContin
®
tablets: assessing comparative preferences and tampering potential
. Journal of Psychopharmacology 27:9, pages 808-816.
Crossref
Crossref
Emma Whelan & Mark Asbridge. (2013) The OxyContin crisis: Problematisation and responsibilisation strategies in addiction, pain, and general medicine journals. International Journal of Drug Policy 24:5, pages 402-411.
Crossref
Crossref
Beatrice Setnik, Kenneth Sommerville, Veeraindar Goli, Ling Han & Lynn Webster. (2013) Assessment of Pharmacodynamic Effects Following Oral Administration of Crushed Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules Compared with Crushed Morphine Sulfate Controlled-Release Tablets and Placebo in Nondependent Recreational Opioid Users. Pain Medicine 14:8, pages 1173-1186.
Crossref
Crossref
Suzanne K. Vosburg, Jermaine D. Jones, Jeanne M. Manubay, Judy B. Ashworth, Douglas Y. Shapiro & Sandra D. Comer. (2013)
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin
®
(non-TRF) in prescription opioid abusers
. Addiction 108:6, pages 1095-1106.
Crossref
Crossref
Hilary D. Wilson, Elizabeth J. Dansie, Myoung S. Kim, Bruce L. Moskovitz, Wing Chow & Dennis C. Turk. (2013) Clinicians' Attitudes and Beliefs About Opioids Survey (CAOS): Instrument Development and Results of a National Physician Survey. The Journal of Pain 14:6, pages 613-627.
Crossref
Crossref
Peter J. Perrino, Salvatore V. Colucci, Glen Apseloff & Stephen C. Harris. (2013) Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults. Clinical Drug Investigation 33:6, pages 441-449.
Crossref
Crossref
Stephen F. Butler, Theresa A. Cassidy, Howard Chilcoat, Ryan A. Black, Craig Landau, Simon H. Budman & Paul M. Coplan. (2013) Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment. The Journal of Pain 14:4, pages 351-358.
Crossref
Crossref
In Cheol HwangJae Yong Shim. (2013) Opioids use for chronic noncancer pain. Journal of the Korean Medical Association 56:8, pages 711.
Crossref
Crossref
Tammi Schaeffer. (2012) Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics. Journal of Medical Toxicology 8:4, pages 400-407.
Crossref
Crossref
Suzanne K. Vosburg, Jermaine D. Jones, Jeanne M. Manubay, Judy B. Ashworth, Irma H. Benedek & Sandra D. Comer. (2012) Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug and Alcohol Dependence 126:1-2, pages 206-215.
Crossref
Crossref
Svetlana Beilfuss. (2019) Pharmaceutical Opioid Marketing and Physician Prescribing Behavior. SSRN Electronic Journal.
Crossref
Crossref